{"id":11097,"date":"2020-10-27T16:28:31","date_gmt":"2020-10-27T10:58:31","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11097"},"modified":"2021-07-24T12:58:08","modified_gmt":"2021-07-24T07:28:08","slug":"latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics","title":{"rendered":"Bayer eyes AskBio\u2019s Gene Therapies; Novartis&#8217; Iptacopan; Forma&#8217;s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a01faf14be42\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a01faf14be42\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\/#Bayer_Set_to_Fork_Over_USD_4_Billion_for_AskBios_Gene_Therapies\" >Bayer Set to Fork Over USD 4 Billion for AskBio\u2019s Gene Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\/#Novartis_Iptacopan_LNP_Shows_Promise_in_C3_Glomerulopathy_C3G\" >Novartis&#8217; Iptacopan (LNP) Shows Promise in C3 Glomerulopathy (C3G)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\/#Forma_Therapeutics_Olutasidenib_Proves_Efficient_in_IDH1-Mutated_AML\" >Forma Therapeutics\u2019 Olutasidenib Proves Efficient in IDH1-Mutated AML<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\/#EpicGenetics_Enters_a_Research_Collaboration_with_Mayo_Clinic_to_Bolster_Fibromyalgia_Diagnostics\" >EpicGenetics Enters a Research Collaboration with Mayo Clinic to Bolster Fibromyalgia Diagnostics<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bayer_Set_to_Fork_Over_USD_4_Billion_for_AskBios_Gene_Therapies\"><\/span><strong>Bayer Set to Fork Over USD 4 Billion for AskBio\u2019s Gene Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Germany-based Bayer is set to acquire North Carolina-based Asklepios BioPharmaceutical (AskBio) with motives to get its hands on its gene therapies.&nbsp;<\/p>\n\n\n\n<p>Bayer will pay USD 2 billion in upfront payment in exchange for AskBio&#8217;s AAV-based gene therapy pipeline treatments for Pompe disease, Parkinson\u2019s disease, and congestive heart failure. Bayer will pay another USD 2 billion in milestone payments.&nbsp;<\/p>\n\n\n\n<p>AskBio leverages its Pro10 AAV manufacturing process that is used by several pharma giants. The company holds several patents in areas such as AAV production, chimeric vectors, and self-complementary DNA. The company\u2019s technology has already proved its worth by winning regulatory approval for gene therapy developed for Spinal muscular atrophy by Illinois-based AveXis, a subsidiary of Novartis. Pfizer is also leveraging AskBio\u2019s proprietary gene-delivery platform for developing novel therapies for patients with Hepatitis C virus (HCV).&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_Iptacopan_LNP_Shows_Promise_in_C3_Glomerulopathy_C3G\"><\/span><strong>Novartis&#8217; Iptacopan (LNP) Shows Promise in C3 Glomerulopathy (C3G)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novartis announced positive interim Phase II results of its most advanced kidney drug, Iptacopan (LNP) in<a href=\"https:\/\/www.delveinsight.com\/report-store\/complement-3-glomerulopathy-c3g-market\" target=\"_blank\" rel=\"noreferrer noopener\"> C3 glomerulopathy (C3G)<\/a> at the virtual American Society of Nephrology (ASN) 2020 Annual Meeting. As per estimates presented by NORD, C3G affects persons 2\u20133 per 1,000,000 people, thus an ultra-rare and severe type of primary glomerulonephritis.<\/p>\n\n\n\n<p>Iptacopan is a first-in-class oral, small molecule that inhibits factor B, which is a key serine protease of the alternative pathway of the complement cascade. The drug is simultaneously under investigation for a number of renal conditions associated with complement system dysregulation, including IgA nephropathy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, and membranous nephropathy.<\/p>\n\n\n\n<p>The drug also received Orphan drug designation a few months ago, won the PRIME designation in C3 glomerulopathy (C3G) that will offer the drug advantage to the patients.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Forma_Therapeutics_Olutasidenib_Proves_Efficient_in_IDH1-Mutated_AML\"><\/span><strong>Forma Therapeutics\u2019 Olutasidenib Proves Efficient in IDH1-Mutated AML<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Forma Therapeutics\u2019 lead candidate, Olutasidenib, has demonstrated clinically efficient and safe activity in Phase II FT2102-HEM-101 clinical trial in patients with relapsed\/refractory (R\/R) <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\" target=\"_blank\" rel=\"noreferrer noopener\">acute myeloid leukemia<\/a> (AML) with mutations in isocitrate dehydrogenase 1 (IDH1m). The company acknowledges that IDH1 mutations occur in 6% to 8% of all the AML patients, in nearly 80% of brain cancer cases including grade 2 and 3 gliomas and secondary glioblastoma.<\/p>\n\n\n\n<p>Olutasidenib is a selective inhibitor of IDH1m, an enzyme, which is responsible for causing blood cancers and solid tumors when mutated. The trial is not only examining olutasidenib as monotherapy in&nbsp; IDH1m AML but in combination with azacitidine or cytarabine in cohorts in patients with IDH1m AML or myelodysplastic syndrome (MDS).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"EpicGenetics_Enters_a_Research_Collaboration_with_Mayo_Clinic_to_Bolster_Fibromyalgia_Diagnostics\"><\/span><strong>EpicGenetics Enters a Research Collaboration with Mayo Clinic to Bolster Fibromyalgia Diagnostics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>EpicGenetics, a privately held biomedical company based in Los Angeles, announced a contract with the Mayo Clinic Fibromyalgia and Chronic Fatigue Clinic to advance research to better diagnose <a href=\"https:\/\/www.delveinsight.com\/report-store\/fibromyalgia-market\" target=\"_blank\" rel=\"noreferrer noopener\">fibromyalgia<\/a>. The duo plans to investigate the use of the EpicGenetics FM\/a Test to determine the test\u2019s use and applicability for the same.\u00a0<\/p>\n\n\n\n<p>Fibromyalgia (FM) is a common rheumatological syndrome characterized by chronic, diffuse musculoskeletal pain, and tenderness with a number of associated symptoms, among which sleep disturbances, fatigue, and affective dysfunction affecting over 20 million patients in the US alone.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer Set to Fork Over USD 4 Billion for AskBio\u2019s Gene Therapies Germany-based Bayer is set to acquire North Carolina-based Asklepios BioPharmaceutical (AskBio) with motives to get its hands on its gene therapies.&nbsp; Bayer will pay USD 2 billion in upfront payment in exchange for AskBio&#8217;s AAV-based gene therapy pipeline treatments for Pompe disease, Parkinson\u2019s [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11100,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[107,349,423,1263,639],"industry":[17225],"therapeutic_areas":[17235,17231,17228],"class_list":["post-11097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bayer","tag-latest-pharma-news","tag-novartis","tag-pharma-collaborations","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bayer acquires AskBio; Novartis&#039; Iptacopan; Forma&#039;s AML Therapy<\/title>\n<meta name=\"description\" content=\"Bayer eyes AskBio\u2019s Gene Therapies; Novartis&#039; Iptacopan; Forma&#039;s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer acquires AskBio; Novartis&#039; Iptacopan; Forma&#039;s AML Therapy\" \/>\n<meta property=\"og:description\" content=\"Bayer eyes AskBio\u2019s Gene Therapies; Novartis&#039; Iptacopan; Forma&#039;s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-27T10:58:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/27162753\/Pharma-news-for-Bayer-Novartis-Forma-AskBio.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer acquires AskBio; Novartis' Iptacopan; Forma's AML Therapy","description":"Bayer eyes AskBio\u2019s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics","og_locale":"en_US","og_type":"article","og_title":"Bayer acquires AskBio; Novartis' Iptacopan; Forma's AML Therapy","og_description":"Bayer eyes AskBio\u2019s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic","og_url":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-10-27T10:58:31+00:00","article_modified_time":"2021-07-24T07:28:08+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/27162753\/Pharma-news-for-Bayer-Novartis-Forma-AskBio.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics","url":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics","name":"Bayer acquires AskBio; Novartis' Iptacopan; Forma's AML Therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/27162753\/Pharma-news-for-Bayer-Novartis-Forma-AskBio.jpg","datePublished":"2020-10-27T10:58:31+00:00","dateModified":"2021-07-24T07:28:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Bayer eyes AskBio\u2019s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/27162753\/Pharma-news-for-Bayer-Novartis-Forma-AskBio.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/27162753\/Pharma-news-for-Bayer-Novartis-Forma-AskBio.jpg","width":772,"height":482,"caption":"Pharma news for Bayer, Novartis, Forma, AskBio"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/27162753\/Pharma-news-for-Bayer-Novartis-Forma-AskBio-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">pharma collaborations<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 27, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 27, 2020 4:28 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Pharma news for Bayer, Novartis, Forma, AskBio","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11097"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11097\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11100"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11097"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11097"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}